Stocks and Investing
Stocks and Investing
Tue, March 5, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
David Amsellem Maintained (AVDL) at Buy with Increased Target to $23 on, Mar 5th, 2024
David Amsellem of Piper Sandler, Maintained "Avadel Pharmaceuticals plc" (AVDL) at Buy with Increased Target from $18 to $23 on, Mar 5th, 2024.
David has made no other calls on AVDL in the last 4 months.
There is 1 other peer that has a rating on AVDL. Out of the 1 peers that are also analyzing AVDL, 0 agree with David's Rating of Hold.
This is the rating of the analyst that currently disagrees with David
- Ashwani Verma of "UBS" Initiated at Strong Buy and Held Target at $21 on, Tuesday, February 6th, 2024
Contributing Sources